Synthetic data only. Never enter patient information; nothing is sent or stored. For clinicians. Not FDA cleared.For licensed clinicians. Educational demonstration on synthetic data. Never enter real patient identifiers or protected health information: everything runs in your browser and nothing is sent or stored. Clinical decision support only; not FDA cleared; physician review is required.
CPE-005 · Classification
LV-02: Steatosis not documented, fibrosis screening indicated
Steatosis not documented, fibrosis screening indicated. Evaluates steatosis not documented.
Active rulePriority 4Liver engine v1.0.0
Condition
- steatosis not documented
- type 2 diabetes OR prediabetes OR at least two cardiometabolic risk factors OR persistently raised ALT
What it reports
- Screening opportunity: AASLD recommends FIB-4 in patients with these risk profiles
Recommended next steps (for physician review)
- Calculate FIB-4
- Consider liver imaging to document steatosis
Diagnostic boundary
- Does not diagnose MASLD; steatosis must be documented.
Evidence
- EV-AASLD-2023Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797-1835.Supports: FIB-4 first for risk stratification; thresholds <1.3 and >2.67; elastography 8 and 12 kPa; ELF 7.7 and 9.8 ALT upper limits near 29–33 U/L (men) and 19–25 U/L (women) Cardiovascular risk is the leading cause of death in MASLD
Cases where this rule fires
Open a case to see this rule fire with real inputs, then change the values until it stops.
Try Biod in your practice
The Clinical Intelligence Layer — transforming fragmented clinical information into structured intelligence for clinician review and action.